Interestingly, BPC 157 has also shown promise in improving gut health
Delving into the science behind these two powerful compounds reveals a fascinating interplay
Nearly all of the evidence behind it comes from animal and in-vitro (preclinical) studies , not from completed human efficacy trials
As for suggestions on novel research ideas which promote attenuation of inflammation in DCM, the researchers have focussed on novel drug targets such as TNF-alpha (an inflammatory biomarker), HOMA-c peptide (a biomarker of insulin resistance), FOXO1 (biomarker for cardiac fibrosis)
Diurnal regulation of the early growth response 1 (Egr-1) protein expression by hepatocyte nuclear factor 4alpha(HNF4alpha) and small heterodimer partner (SHP) cross-talk in liver fibrosis
The progress made this year is setting the stage for 2026, as healthcare and clinical research work together toward a healthier future for all